Decortin

Phase 3Small molecule

SSTZ eyetrial

Decortin is one of 9 small molecule programs targeting Intermediate Uveitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Intermediate UveitisActive, not recruiting

Intermediate UveitisPhase 3

Active, not recruiting

Competition

Competitive Landscape

8 competitors in Intermediate Uveitis

#DrugCompanyPhaseTrials

Rayos

RRoxane Laboratories

Approved

—2

Decadron

AAspen Global Incorporated

Approved

—3

Lupkynis

Aurinia Pharmaceuticals

Approved

—4

Trexall

Alnylam Pharmaceuticals

Phase 3

1 5

Cellcept

Myfortic

1 7

Interferon-Beta

Biogen

Phase 3

1 8

Actemra

Decortin

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Intermediate Uveitis1 trial

Myfortic for the Treatment of Non-infectious Intermediate Uveitis

Completed·SSTZ eyetrial·Phase 3·NCT01092533·44 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Decortin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Decortin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Decortin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — STZ eyetrial company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SSTZ eyetrial

Decortin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Intermediate Uveitis1 trial

References

Drug Info

Quick Facts

Related News